Catheter design was key for the Boston Scientific Farapulse pulsed field ablation system

Boston Scientific Chief Medical Officer Dr. Ken Stein explains how catheter design drives the Farapulse pulsed field ablation system.

This image depicts the Boston Scientific Farapulse PFA system’s Farawave ablation catheter in its flower shape. [Image courtesy of Boston Scientific]

Following FDA approval on Jan. 31, Farapulse from Boston Scientific is now the second pulsed field ablation (PFA) system approved to treat atrial fibrillation (AFib) in the U.S.

Medtronic’s PulseSelect PFA System picked up the first FDA approval in December for the treatment of paroxysmal and persistent AFib.

Boston Scientific’s Farapulse, on the other hand, is indicated for the isolation of pulmonary veins to treat drug-refractory, recurrent, symptomatic, paroxysmal AFib.

Farapulse delivers pulsed field energy using the Farawave ablation catheter, Farastar ablation generator and Faradrive steerable s…

Read more
  • 0

Medtronic CEO: ‘Our top priority is restoring our earnings power — full stop.’

Medtronic Chair and CEO Geoff Martha [Photo courtesy of Medtronic]Medtronic (NYSE: MDT) + Chair and CEO Geoff Martha focused on the push for profits at the world’s largest medical device manufacturer in his presentation at the J.P. Morgan Healthcare Conference today.

“Our top priority is restoring our earnings power — full stop,” he said, citing Medtronic’s recent reorganizations and changes to incentives, product approvals and launches, and new initiatives like the Medtronic AI Center of Excellence.

“We continue to be this mission-driven company that you know Medtronic to be and our customers and patients know Medtronic to be, but at the same time, performance driven,” he said. “You’ve got to be both. It’s not one without the other: no margin, no mission.”

Martha also offered details of Medtronic’s efforts to leverage its buying power and improve ef…

Read more
  • 0

What’s so special about pulsed field ablation? Medtronic EVP Sean Salmon explains

The Medtronic PulseSelect Pulsed Field Ablation (PFA) System is designed to treat paroxysmal and persistent atrial fibrillation (AFIb). [Image courtesy of Medtronic]

Medtronic’s PulseSelect Pulsed Field Ablation (PFA) System — which won the first FDA approval for PFA to treat atrial fibrillation (AFib) — is just the start of a wave of new PFA devices expected to hit the market.

Medtronic is lining up another PFA cardiac ablation system for approval, while competitor Boston Scientific anticipates approval of its Farapulse PFA system sometime in 2024. Meanwhile, Johnson & Johnson’s Biosense Webster is testing its ThermoCool SmartTouch SF system for both PFA and radiofrequency ablation.

Medtronic EVP and Cardiovascular President Sean Salmon recently discussed PFA technology in an interview with Medical Design & Outsourcing before the world’s largest medical device manufacturer anno…

Read more
  • 0